Cardarine (GW-501516) vs MK-677 (Ibutamoren)

Mechanism

Cardarine is a selective peroxisome proliferator-activated receptor delta (PPARd) agonist, not a SARM (it does not bind the androgen receptor). PPARd activation in skeletal muscle upregulates genes for fatty acid oxidation (CPT1B, PDK4, ACOX1), shifting fuel substrate from glycolysis toward beta-oxidation, effectively increasing endurance capacity and fat utilization. It increases oxidative type I (slow-twitch) muscle fiber proportion, enhances mitochondrial biogenesis via PGC-1a coactivation, reduces circulating triglycerides and LDL, and increases HDL cholesterol. PPARd activation also reduces macrophage-mediated inflammation through NF-kB suppression.

Standard Dosing

Research indicates 10-20 mg daily orally for 8-12 weeks. Clinical trials (metabolic syndrome) used 2.5-10 mg/day.

Timing

Once daily, 1-2 hours before exercise for acute endurance benefit. Half-life approximately 16-24 hours. Consistent daily dosing.

Cycle Duration

8-12 week cycles. No HPG suppression, so PCT is not required. However, long-term safety is unknown and cycling is prudent.

Side Effects

• CANCER RISK: Accelerated tumor development in multiple organs observed in 2-year rodent study at all doses tested
• Headache
• Nausea
• Diarrhea
• Potential liver effects at high doses

Contraindications

• Active or history of cancer (CRITICAL — see notes on carcinogenicity)
• Pregnancy and breastfeeding
• Individuals under 21
• Liver disease

Best Stacking Partners

Mechanism

MK-677 (ibutamoren) is an orally active, non-peptide growth hormone secretagogue that mimics ghrelin by binding the ghrelin receptor (GHSR1a) in the hypothalamus and pituitary. This triggers pulsatile growth hormone release via the same physiological mechanism as endogenous ghrelin, preserving the natural episodic GH secretion pattern. MK-677 increases GH, IGF-1, and IGFBP-3 levels to those observed in young adults without affecting cortisol levels. It also stimulates appetite through ghrelin receptor activation in the hypothalamus. Unlike exogenous GH injection, MK-677 maintains the pulsatile GH pattern and stimulates all five GH isoforms.

Standard Dosing

Research indicates 10-25 mg daily orally. Clinical trials used 25 mg/day. 10-15 mg may provide GH elevation with fewer side effects.

Timing

Take 30-60 minutes before bedtime. This timing leverages the natural nocturnal GH pulse, maximizes sleep quality benefits, and minimizes daytime appetite increase. Half-life ~24 hours ensures once-daily dosing is sufficient.

Cycle Duration

Can be used continuously for months to years — no cycling required as it works through physiological GH release mechanisms. Clinical trials ran for up to 2 years. Reassess IGF-1 and metabolic markers every 3-6 months.

Side Effects

• Increased appetite (ghrelin mimetic — significant and persistent)
• Water retention and bloating (GH-mediated)
• Numbness and tingling (carpal tunnel-like symptoms)
• Elevated fasting blood glucose and insulin resistance
• Lethargy and increased sleep depth
• Vivid dreams
• Joint pain (less common than exogenous GH)

Contraindications

• Active malignancy (GH/IGF-1 promotes cell proliferation)
• Diabetes mellitus (impairs glucose tolerance — use with extreme caution)
• Active diabetic retinopathy
• History of pituitary tumors
• Congestive heart failure (fluid retention)

Best Stacking Partners